News

Ikarovec to Present at LSX Investival Showcase During London Life Sciences Week

CSO Katie Binley, PhD to showcase dual-pathway gene therapy approach for Geographic Atrophy

Norwich, UK – [Date] – Ikarovec Limited today announced that Chief Scientific Officer Katie Binley, PhD will present at the LSX Investival Showcase on Monday, November 17th, 2025, during London Life Sciences Week (November 16-21).

Dr. Binley will deliver a showcase presentation titled “Dual-Pathway Gene Therapy for Geographic Atrophy” during the LSX Biotech session from 11:50 AM to 12:00 PM GMT. The presentation will highlight IKAR-001’s differentiated approach combining neuroprotection with complement modulation to preserve vision in patients with geographic atrophy.

“We’re excited to share our progress with the global investment community at this premier life sciences event,” said Thomas Ciulla, MD, MBA, President and CEO of Ikarovec. “LSX Investival provides an excellent platform to engage with investors and partners who share our vision of transforming treatment for retinal degenerative diseases.”

About LSX Investival

LSX Investival is Europe’s leading biotech partnering and investment event, bringing together visionary leaders, investors, and innovators across the life sciences sector during London Life Sciences Week. The event facilitates strategic connections between emerging biotech companies and the global investment community.

Both Dr. Ciulla and Dr. Binley will be available for one-on-one meetings throughout the conference. Investors and partners interested in learning more about Ikarovec’s dual-pathway gene therapy platform are encouraged to reach out to schedule a meeting.

About Ikarovec

Ikarovec is pioneering dual-pathway gene therapies for retinal degenerative diseases. The company’s proprietary bicistronic platform enables the expression of two synergistic therapeutic proteins from a single gene therapy vector, addressing multiple disease pathways simultaneously.

Led by an experienced management team with proven exits including Luxturna (Spark Therapeutics, $4.8B to Roche), Izervay (Iveric Bio, $5.9B to Astellas), and EyeBio ($3.0B to Merck), Ikarovec is backed by LifeArc Ventures, Parkwalk Advisors, and UKI2S.

For more information, visit www.ikarovec.com or follow us on LinkedIn.